These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 9085318)

  • 21. Outpatient therapy with oral ofloxacin for patients with low risk neutropenia and fever: a prospective, randomized clinical trial.
    Hidalgo M; Hornedo J; Lumbreras C; Trigo JM; Colomer R; Perea S; Gómez C; Ruiz A; García-Carbonero R; Cortés-Funes H
    Cancer; 1999 Jan; 85(1):213-9. PubMed ID: 9921995
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost of Gram-negative resistance.
    Evans HL; Lefrak SN; Lyman J; Smith RL; Chong TW; McElearney ST; Schulman AR; Hughes MG; Raymond DP; Pruett TL; Sawyer RG
    Crit Care Med; 2007 Jan; 35(1):89-95. PubMed ID: 17110877
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-effective management of complicated urinary tract infections.
    Cox CE
    Adv Ther; 1995; 12(4):222-35. PubMed ID: 10155350
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacoepidemiology of ciprofloxacin: analysis of use patterns and cost impact.
    Marchbanks CR; Graham KK; Barnes J; Dudley MN
    Pharmacotherapy; 1991; 11(1):50-5. PubMed ID: 2020611
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The economic effect of oral linezolid versus intravenous vancomycin in the outpatient setting: the payer perspective.
    McKinnon PS; Carter CT; Girase PG; Liu LZ; Carmeli Y
    Manag Care Interface; 2007 Jan; 20(1):23-34. PubMed ID: 17310650
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pressure ulcers, hospital complications, and disease severity: impact on hospital costs and length of stay.
    Allman RM; Goode PS; Burst N; Bartolucci AA; Thomas DR
    Adv Wound Care; 1999; 12(1):22-30. PubMed ID: 10326353
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Use of ciprofloxacin in the treatment of hospitalized patients with intra-abdominal infections.
    Madan AK
    Clin Ther; 2004 Oct; 26(10):1564-77. PubMed ID: 15598473
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost of oral antibiotic therapy.
    Nightingale CH; Quintiliani R
    Pharmacotherapy; 1997; 17(2):302-7. PubMed ID: 9085322
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost effectiveness of a clinical pharmacist on a neurosurgical team.
    Weant KA; Armitstead JA; Ladha AM; Sasaki-Adams D; Hadar EJ; Ewend MG
    Neurosurgery; 2009 Nov; 65(5):946-50; discussion 950-1. PubMed ID: 19834408
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Correlates and Economic and Clinical Outcomes of an Adult IV to PO Antimicrobial Conversion Program at an Academic Medical Center in Midwest United States.
    Sallach-Ruma R; Nieman J; Sankaranarayanan J; Reardon T
    J Pharm Pract; 2015 Jun; 28(3):238-48. PubMed ID: 24399573
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Training patients to administer intravenous antibiotics at home.
    Swenson JP
    Am J Hosp Pharm; 1981 Oct; 38(10):1480-3. PubMed ID: 7294042
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Physician opinion of pharmacist-initiated change from injectable to oral administration of histamine H2-receptor antagonists.
    Kirking DM; Bickley SK; Wasserman ML
    Am J Hosp Pharm; 1991 Aug; 48(8):1722-7. PubMed ID: 1680293
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The impact of a pharmacist-managed dosage form conversion service on ciprofloxacin usage at a major Canadian teaching hospital: a pre- and post-intervention study.
    Ho BP; Lau TT; Balen RM; Naumann TL; Jewesson PJ
    BMC Health Serv Res; 2005 Jun; 5():48. PubMed ID: 15987523
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Implementing a pharmacist-led sequential antimicrobial therapy strategy: a controlled before-and-after study.
    Dunn K; O'Reilly A; Silke B; Rogers T; Bergin C
    Int J Clin Pharm; 2011 Apr; 33(2):208-14. PubMed ID: 21744190
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Development of an intravenous-to-oral route conversion program for antimicrobial therapy at a Canadian tertiary care health facility.
    Zamin MT; Pitre MM; Conly JM
    Ann Pharmacother; 1997 May; 31(5):564-70. PubMed ID: 9161649
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical and economic impact of intravenous to oral conversion therapy programs.
    Nadeau MC; Kuti EL
    Conn Med; 2011 Jan; 75(1):25-9. PubMed ID: 21329289
    [No Abstract]   [Full Text] [Related]  

  • 37. Clinical and economic impact of a pharmacist-intervention to promote sequential intravenous to oral clindamycin conversion.
    Martínez MJ; Freire A; Castro I; Inaraja MT; Ortega A; Del Campo V; Rodriguez I; Bardán B; Morano LE; Garcia JF
    Pharm World Sci; 2000 Apr; 22(2):53-8. PubMed ID: 10849923
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Economic impact of oral ciprofloxacin. A pharmacist's perspective.
    Barriere SL
    Am J Med; 1987 Apr; 82(4A):387-90. PubMed ID: 3578327
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical and economic impact of a pharmacist-managed i.v.-to-p.o. conversion service for levofloxacin in Taiwan.
    Yen YH; Chen HY; Wuan-Jin L; Lin YM; Shen WC; Cheng KJ
    Int J Clin Pharmacol Ther; 2012 Feb; 50(2):136-41. PubMed ID: 22257579
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Good clinical practices and inpatient antibiotics: optimization of fluoroquinolone switch therapy].
    Rigaud B; Malbranche C; Pioud V; Lochard A; Chemelle M; Aube H; Lazzarotti A; Guignard MH
    Presse Med; 2007 Sep; 36(9 Pt 1):1159-66. PubMed ID: 17449219
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.